Glatiramer Acetate Patent Expiration
Glatiramer Acetate is Used for treating multiple sclerosis. It was first introduced by Teva Pharmaceuticals Usa
Glatiramer Acetate Patents
Given below is the list of patents protecting Glatiramer Acetate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Copaxone | US8232250 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US8399413 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US8969302 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US9155776 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US9402874 | Low frequency glatiramer acetate therapy | Aug 19, 2030 | Teva Pharms Usa |
| Copaxone | US5981589 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6054430 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6054430 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6342476 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6362161 | Copolymer-1 improvements on compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6362161 | Copolymer-1 improvements on compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6620847 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US6939539 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US7199098 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US7199098 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US8367605 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
| Copaxone | US8367605 | Copolymer-1 improvements in compositions of copolymers |
May 24, 2014
(Expired) | Teva Pharms Usa |
Glatiramer Acetate's Family Patents
Explore Our Curated Drug Screens
Glatiramer Acetate Generic API Manufacturers
Several generic applications have been filed for Glatiramer Acetate. The first generic version for Glatiramer Acetate was by Sandoz Inc and was approved on Apr 16, 2015. And the latest generic version is by Synthon Pharmaceuticals Inc and was approved on Sep 25, 2024.
Given below is the list of companies who have filed for Glatiramer Acetate generic, along with the locations of their manufacturing plants worldwide.
1. MYLAN
Mylan Pharmaceuticals Inc has filed for 2 different strengths of generic version for Glatiramer Acetate. Given below are the details of the strengths of this generic introduced by Mylan.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Oct 3, 2017 |
| 20MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Oct 3, 2017 |
Manufacturing Plant Locations New
Mylan's manufacturing plants are situated in 4 countries - United States, India, Canada, Ireland. Given below are the details of these plant locations as well as the firm names of Mylan as present at those locations.
| Country | City | Firm Name | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||||||
| India |
| |||||||||||||||||
| Canada |
| |||||||||||||||||
| Ireland |
| |||||||||||||||||
2. SANDOZ
Sandoz Inc has filed for 2 different strengths of generic version for Glatiramer Acetate. All of these versions come by the name GLATOPA. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 20MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Apr 16, 2015 |
| 40MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Feb 12, 2018 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
3. SYNTHON PHARMS INC
Synthon Pharmaceuticals Inc has filed for 2 different strengths of generic version for Glatiramer Acetate. Given below are the details of the strengths of this generic introduced by Synthon Pharms Inc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Sep 25, 2024 |
| 20MG/ML | injectable | Prescription | SUBCUTANEOUS | AP | Sep 25, 2024 |